ACADIA Pharmaceuticals ACAD Stock
ACADIA Pharmaceuticals Price Chart
ACADIA Pharmaceuticals ACAD Financial and Trading Overview
| ACADIA Pharmaceuticals stock price | 14.79 USD |
| Previous Close | 24.14 USD |
| Open | 24.15 USD |
| Bid | 0 USD x 1100 |
| Ask | 0 USD x 1000 |
| Day's Range | 24.07 - 24.58 USD |
| 52 Week Range | 12.24 - 26.04 USD |
| Volume | 1.06M USD |
| Avg. Volume | 1.41M USD |
| Market Cap | 3.97B USD |
| Beta (5Y Monthly) | 0.525352 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.98 USD |
ACAD Valuation Measures
| Enterprise Value | 3.73B USD |
| Trailing P/E | N/A |
| Forward P/E | 2439 |
| PEG Ratio (5 yr expected) | -1.79 |
| Price/Sales (ttm) | 7.62438 |
| Price/Book (mrq) | 10.581345 |
| Enterprise Value/Revenue | 7.167 |
| Enterprise Value/EBITDA | -22.982 |
Trading Information
ACADIA Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.525352 |
| 52-Week Change | 25.01% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 26.04 USD |
| 52 Week Low | 12.24 USD |
| 50-Day Moving Average | 22 USD |
| 200-Day Moving Average | 18.47 USD |
ACAD Share Statistics
| Avg. Volume (3 month) | 1.41M USD |
| Avg. Daily Volume (10-Days) | 1.19M USD |
| Shares Outstanding | 162.62M |
| Float | 110.72M |
| Short Ratio | 6.54 |
| % Held by Insiders | 0.22% |
| % Held by Institutions | 97.70% |
| Shares Short | 10.04M |
| Short % of Float | 8.27% |
| Short % of Shares Outstanding | 6.16% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -28.053% |
| Operating Margin (ttm) | -31.55% |
| Gross Margin | 29.07% |
| EBITDA Margin | -31.18% |
Management Effectiveness
| Return on Assets (ttm) | -16.037% |
| Return on Equity (ttm) | -35.63% |
Income Statement
| Revenue (ttm) | 520.23M USD |
| Revenue Per Share (ttm) | 3.21 USD |
| Quarterly Revenue Growth (yoy) | 2.60% |
| Gross Profit (ttm) | 145.49M USD |
| EBITDA | -162228000 USD |
| Net Income Avi to Common (ttm) | -145940000 USD |
| Diluted EPS (ttm) | -0.93 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 402.87M USD |
| Total Cash Per Share (mrq) | 2.48 USD |
| Total Debt (mrq) | 60.61M USD |
| Total Debt/Equity (mrq) | 16.2 USD |
| Current Ratio (mrq) | 2.242 |
| Book Value Per Share (mrq) | 2.305 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -55639000 USD |
| Levered Free Cash Flow (ttm) | 68.01M USD |
Profile of ACADIA Pharmaceuticals
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 12830 El Camino Real |
| ZIP | 92130 |
| Phone | 858 558 2871 |
| Website | https://acadia.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 540 |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.
Q&A For ACADIA Pharmaceuticals Stock
What is a current ACAD stock price?
ACADIA Pharmaceuticals ACAD stock price today per share is 14.79 USD.
How to purchase ACADIA Pharmaceuticals stock?
You can buy ACAD shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ACADIA Pharmaceuticals?
The stock symbol or ticker of ACADIA Pharmaceuticals is ACAD.
Which industry does the ACADIA Pharmaceuticals company belong to?
The ACADIA Pharmaceuticals industry is Biotechnology.
How many shares does ACADIA Pharmaceuticals have in circulation?
The max supply of ACADIA Pharmaceuticals shares is 165.22M.
What is ACADIA Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
ACADIA Pharmaceuticals PE Ratio is now.
What was ACADIA Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
ACADIA Pharmaceuticals EPS is 0 USD over the trailing 12 months.
Which sector does the ACADIA Pharmaceuticals company belong to?
The ACADIA Pharmaceuticals sector is Healthcare.
ACADIA Pharmaceuticals ACAD included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16685.97 USD — |
-0.07
|
9.35B USD — | 16613.84 USD — | 16726.41 USD — | — - | 9.35B USD — |
| Dow Jones U.S. Biotechnology In DJUSBT | 2884.66 USD — |
+0.15
|
64.52M USD — | 2863.3 USD — | 2885.33 USD — | — - | 64.52M USD — |
| NASDAQ Composite Total Return I XCMP | 20297.03 USD — |
-0.07
|
— — | 20209.29 USD — | 20346.22 USD — | — - | — — |
| Nasdaq US Smart Pharmaceuticals NQSSPH | 1438.76 USD — |
-0.1
|
— — | 1432.45 USD — | 1440.65 USD — | — - | — — |
| Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2638.24 USD — |
+0.04
|
— — | 2629.06 USD — | 2646.37 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4440.08 USD — |
-0.29
|
— — | 4419.86 USD — | 4453.74 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 997.91 USD — |
-0.28
|
— — | 994.33 USD — | 1001 USD — | — - | — — |
| NASDAQ Biotechnology Total Retu XNBI | 4763.32 USD — |
-0.45
|
— — | 4749.23 USD — | 4785.63 USD — | — - | — — |
| Nasdaq US 700 Small Cap Index NQUS700SC | 2163.87 USD — |
-0.06
|
— — | 2159.79 USD — | 2170.83 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 8125.97 USD — |
-0.04
|
— — | 8115.65 USD — | 8142.92 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}